- PRODUCT NAME
- DISEASE AREA
Filter by
-
CONTENT TYPE
Would you like to submit a medical inquiry?
Would you like to connect with an MSL?
Search result(s) may include information that is not consistent with the product’s Full Prescribing Information. Eisai does not recommend uses that are inconsistent with the Full Prescribing Information.
Please note that LEQEMBI (lecanemab-irmb) is approved only for those indications and dosages that appear in the LEQEMBI Full Prescribing Information. The information below and/or its appendices may summarize publications or guidelines that describe indications or treatment modalities for the use of LEQEMBI that have not been approved by the Food and Drug Administration.
The information below is provided by Eisai Inc. and is intended to assist you in forming your own clinical conclusions regarding the use of Eisai products. Eisai Inc. does not recommend or endorse the use of this product in any manner other than as described in the Full Prescribing Information.
Adverse reactions, some of which can be serious or fatal, may occur with LEQEMBI, including Amyloid Related Imaging Abnormalities and Infusion-Related Reactions. Click here for Important Safety Information.
LEQEMBI is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied. This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with LEQEMBI. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial.
Prescribing Information for LEQEMBI® (lecanemab-irmb), including Boxed WARNING VIEW/DOWNLOAD
Please note that DAYVIGO (lemborexant) CIV is approved only for those indications and dosages that appear in the DAYVIGO Full Prescribing Information. The information below and/or its appendices may summarize publications or guidelines that describe indications or treatment modalities for the use of DAYVIGO that have not been approved by the Food and Drug Administration.
The information below is provided by Eisai Inc. and is intended to assist you in forming your own clinical conclusions regarding the use of Eisai products. Eisai Inc. does not recommend or endorse the use of this product in any manner other than as described in the Full Prescribing Information.
DAYVIGO is contraindicated in patients with narcolepsy. Adverse reactions, some of which can be serious or fatal, may occur with DAYVIGO, including Central Nervous System (CNS) depressant effects and daytime impairment, sleep paralysis, hynagogic/hypnopompic hallucinations and cataplexy-like symptoms, complex sleep behaviors and worsening of depression/suicidal ideation. The effect of DAYVIGO on respiratory function should be considered for patients with compromised respiratory function. Treatment of insomnia should be initiated only after careful evaluation for comorbid diagnoses. Click here for Important Safety Information.
DAYVIGO is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Prescribing Information for DAYVIGO® (lemborexant) CIV VIEW/DOWNLOAD
Prescribing Information for LEQEMBI® (lecanemab-irmb), including Boxed WARNING VIEW/DOWNLOAD
Prescribing Information for DAYVIGO® (lemborexant) CIV VIEW/DOWNLOAD
Prescribing Information for BANZEL® (rufinamide): VIEW/DOWNLOAD
Please note that Banzel is approved for those indications and dosages that appear in the enclosed Banzel Full Prescribing Information. The enclosed information and/or its appendices may summarize publications or guidelines that describe indications or treatment modalities for the use of Banzel that have not been approved by the Food and Drug Administration.
The enclosed information is provided by Eisai Inc. and is intended to assist you in forming your own clinical conclusions regarding Eisai products. Eisai Inc. does not recommend or endorse the use of this product in any manner other than as described in the Full Prescribing Information.
Click here for Important Safety Information.
Prescribing Information for BANZEL® (rufinamide): VIEW/DOWNLOAD
Eisai does not recommend or endorse the use of this investigational agent in any manner as it has not been approved by the U.S. Food and Drug Administration. This information discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy, safety, or appropriate use. There is no guarantee that such agent will successfully complete clinical development or gain health authority approval. Please do not distribute or copy the attached information. Please refine your search criteria or submit a medical inquiry
Eisai does not recommend or endorse the use of this investigational agent in any manner as it has not been approved by the U.S. Food and Drug Administration. This information discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy, safety, or appropriate use. There is no guarantee that such agent will successfully complete clinical development or gain health authority approval. Please do not distribute or copy the attached information. Please refine your search criteria or submit a medical inquiry
Eisai does not recommend or endorse the use of this investigational agent in any manner as it has not been approved by the U.S. Food and Drug Administration. This information discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy, safety, or appropriate use. There is no guarantee that such agent will successfully complete clinical development or gain health authority approval. Please do not distribute or copy the attached information. Please refine your search criteria or submit a medical inquiry
Eisai does not recommend or endorse the use of this investigational agent in any manner as it has not been approved by the U.S. Food and Drug Administration. This information discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy, safety, or appropriate use. There is no guarantee that such agent will successfully complete clinical development or gain health authority approval. Please do not distribute or copy the attached information. Please refine your search criteria or submit a medical inquiry
Unfortunately, those search terms did not yield results. Please modify search terms or submit a medical inquiry below.
Submit Medical InquiryWould you like to submit a medical inquiry?
Would you like to connect with an MSL?